← Back to Search

Robotic Ankle Assist Device for Cerebral Palsy

Phase 1
Waitlist Available
Led By Ray Browning, PhD
Research Sponsored by BiOMOTUM, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 20 degrees of passive ankle plantar flexion range of motion
Age between 8-18 years
Must not have
Knee extension or ankle dorsiflexion contractures greater than 15 degrees
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minutes pre/post
Awards & highlights

Summary

This trial is testing a robotic device that helps move the ankle to improve walking. It targets children with Cerebral Palsy who have difficulty walking. The device either helps the ankle push off the ground or provides resistance to strengthen muscles. Researchers hope this will help children walk faster and farther. The use of robotic devices for ankle rehabilitation in children with cerebral palsy has been explored in various studies, showing potential benefits in improving ankle mobility and walking ability.

Who is the study for?
This trial is for children aged 8-18 with cerebral palsy who can follow simple instructions and walk for at least six minutes. They should be within the typical height, weight, or BMI range for their condition and able to do some heel raises. Those with recent surgeries or other health issues that could interfere are not eligible.
What is being tested?
The study tests a Robotic Ankle Assist Device (RAAD) designed to improve walking speed and distance in kids with CP. It includes personal-use trials, feedback collection for product design, comparison of RAAD therapy against standard gait training, and a 4-week intervention assessing mobility improvements.
What are the potential side effects?
While specific side effects aren't listed, potential risks may include discomfort from wearing the device or muscle fatigue due to new types of movement during therapy sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can move my ankle downwards at least 20 degrees.
Select...
I am between 8 and 18 years old.
Select...
My height, weight, and BMI are within the typical range for children with CP.
Select...
I can do 5 heel raises with little help for balance.
Select...
I have been diagnosed with cerebral palsy.
Select...
I can walk for 6 minutes, with or without help.
Select...
I can walk with or without limitations.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My knee or ankle cannot fully straighten, bending more than 15 degrees.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of the study visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of the study visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in lower extremity muscle activity similarity to the average unimpaired activity pattern
Change in preferred walking speed
PF activity
Secondary study objectives
6MWT
Ankle muscle co-contraction
COT
+10 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: User testingExperimental Treatment1 Intervention
Two sessions of user-centric testing.
Group II: Therapist-guided trainingExperimental Treatment1 Intervention
Therapist-guided gait training with the RAAD.
Group III: Therapist supervised resistance trainingExperimental Treatment1 Intervention
Resistance training with the RAAD under therapist supervision.
Group IV: Parent supervised resistance trainingExperimental Treatment1 Intervention
Resistance training under parent supervision.
Group V: Assistance trainingExperimental Treatment1 Intervention
Assistance training with the RAAD

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Cerebral Palsy (CP) focus on improving mobility and muscle function. Physical and occupational therapy enhance motor skills through repetitive, goal-directed activities. Botulinum toxin injections reduce spasticity by blocking nerve signals to muscles, improving movement and reducing pain. Robotic-assisted devices, such as the Robotic Ankle Assist Device (RAAD), provide targeted therapy by assisting and resisting movements, which strengthens muscles and improves gait. These treatments are essential for CP patients as they address motor impairments, enhance mobility, and improve overall quality of life.
Effects of upper limb robot-assisted therapy on motor recovery of subacute stroke patients: a kinematic approach.Improved gait parameters after robotic-assisted locomotor treadmill therapy in a 6-year-old child with cerebral palsy.

Find a Location

Who is running the clinical trial?

Northern Arizona UniversityOTHER
33 Previous Clinical Trials
6,735 Total Patients Enrolled
5 Trials studying Cerebral Palsy
99 Patients Enrolled for Cerebral Palsy
Gillette Children's Specialty HealthcareOTHER
30 Previous Clinical Trials
11,454 Total Patients Enrolled
13 Trials studying Cerebral Palsy
5,833 Patients Enrolled for Cerebral Palsy
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,014 Previous Clinical Trials
2,696,805 Total Patients Enrolled
31 Trials studying Cerebral Palsy
8,756 Patients Enrolled for Cerebral Palsy

Media Library

Robotic Ankle Assist Device (RAAD) Clinical Trial Eligibility Overview. Trial Name: NCT04516343 — Phase 1
Cerebral Palsy Research Study Groups: Assistance training, Parent supervised resistance training, Therapist-guided training, User testing, Therapist supervised resistance training
Cerebral Palsy Clinical Trial 2023: Robotic Ankle Assist Device (RAAD) Highlights & Side Effects. Trial Name: NCT04516343 — Phase 1
Robotic Ankle Assist Device (RAAD) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04516343 — Phase 1
~6 spots leftby Sep 2025